NICE rebuffs Yondelis

The U.K.'s NICE issued draft guidance recommending against the use of Yondelis trabectedin from PharmaMar S.A. (Madrid, Spain) in combination with pegylated liposomal doxorubicin hydrochloride (PLDH) to treat relapsed ovarian cancer -- its approved indication. The appraisal committee said the cost of Yondelis was too high relative to its "uncertain benefits," even with a patient access scheme in which PharmaMar would pay the cost of Yondelis after the fifth cycle of treatment. ...